Read by QxMD icon Read

Rhesus isoimmunization

L Pasquini, V Seravalli, G Sisti, C Battaglini, F Nepi, R Pelagalli, M Di Tommaso
OBJECTIVE: The aim of this study was to evaluate the rate of women with polyhydramnios who eventually screened positive to infectious disease by serum screening testing for TORCH and parvovirus B19. METHODS: This is a retrospective observational study on singleton pregnancies with a diagnosis of polyhydramnios and who had serum screening for TORCH and parvovirus B19. Patients were followed with serial ultrasounds between 2006 and 2013. Maternal characteristics, medical and obstetric history were reviewed...
March 2016: Prenatal Diagnosis
Michael Sgro, Sharmilaa Kandasamy, Vibhuti Shah, Marianna Ofner, Douglas Campbell
OBJECTIVES: To estimate the incidence of severe neonatal hyperbilirubinemia in Canada from 2011-2013 following the implementation of the Canadian Pediatric Society's published guidelines on the management of hyperbilirubinemia in 2007. Our previously reported incidence of hyperbilirubinemia in Canada was 1 in 2480. STUDY DESIGN: Term infants ≤ 60 days of age, with a peak serum total bilirubin level > 425 μmol/L or who had an exchange transfusion were followed prospectively through the Canadian Pediatric Surveillance Program from 2011-2013...
April 2016: Journal of Pediatrics
Angela McGillivray, Jan Polverino, Nadia Badawi, Nick Evans
OBJECTIVES: To determine the incidence, causes, associated factors, and short-term outcomes of extreme neonatal hyperbilirubinemia in Australia in order to identify opportunities for prevention. STUDY DESIGN: This was a prospective population-based surveillance study in collaboration with the Australian Pediatric Surveillance Unit between April 1, 2010, and March 31, 2013. Case definition was: infants >34 weeks gestation with a peak total serum bilirubin ≥450 μmol/L and or clinical evidence of bilirubin encephalopathy...
January 2016: Journal of Pediatrics
L Teitelbaum, A Metcalfe, G Clarke, J S Parboosingh, R D Wilson, J M Johnson
OBJECTIVE: Non-invasive fetal Rhesus (Rh) D genotyping, using cell-free fetal DNA (cffDNA) in the maternal blood, allows targeted antenatal anti-RhD prophylaxis in unsensitized RhD-negative pregnant women. The purpose of this study was to determine the cost and benefit of this approach as compared to routine antenatal anti-RhD prophylaxis for all unsensitized RhD-negative pregnant women, as is the current policy in the province of Alberta, Canada. METHODS: This study was a decision analysis based on a theoretical population representing the total number of pregnancies in Alberta over a 1-year period (n = 69 286)...
January 2015: Ultrasound in Obstetrics & Gynecology
H Chambost
Rhesus (Rh) antigens are not expressed on platelets but residual red cells carry the risk of anti-D iso-immunization in transfusion recipients of platelet concentrates (PC). The main theoretical risk associated with this reaction relates to female subjects due to potential obstetrical situations of maternal-foetal Rh incompatibility. Isogroup PC transfusion in this system is therefore advised. However, logistical constraints impose frequent Rh-incompatible transfusions that require the recommendation of anti-Rh immunoglobulin in a girl of childbearing age in this situation...
November 2014: Transfusion Clinique et Biologique: Journal de la Société Française de Transfusion Sanguine
Jing Fan, Brian K Lee, Agneta T Wikman, Stefan Johansson, Marie Reilly
BACKGROUND: Although the risks of adverse pregnancy outcomes associated with anti-D antibodies are well-recognized, much less is known concerning alloimmunization with other red blood cell antibodies detected during routine maternal screening. To date, most reports of adverse pregnancy outcomes associated with non-anti-D antibodies have been from small case studies. The aim of this study was to examine the associations of maternal alloimmunization with specific red blood cell antibodies and the risks of preterm birth and stillbirth in the Swedish population...
August 2014: International Journal of Epidemiology
Arzu Akdağ, Omer Erdeve, Nurdan Uraş, Yavuz Simşek, Uğur Dilmen
OBJECTIVE: While routine administration of rhesus (Rh) immunoglobulin has significantly reduced the incidence of Rh alloimmunization, maternal alloimmunization to other red cell antigens remains a contributor to perinatal morbidity and mortality. Although the Kell antigen is seen on the red cells of only 9% of the general population, attention to Kell antibodies continues to increase. CASE REPORT: A case of fetal hydrops was sonographically detected at 30 weeks of gestation...
March 2012: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
C S Sheeladevi, S Suchitha, G V Manjunath, Srinivas Murthy
The Rhesus (Rh) blood group is one of the most complex blood groups known in humans. It has remained of primary importance in obstetrics, being the main cause of hemolytic disease of the newborn (HDN). Anti-D causes the most severe form of HDN. Other Rh allo antibodies that are capable of causing severe HDN include anti-c, which clinically is the most important Rh antigen after the D antigen. We report a case of hemolytic disease of the newborn due to Rh anti-c in an infant of an Rh positive mother.
September 2013: Indian Journal of Hematology & Blood Transfusion
Vinod K Bhutani, Alvin Zipursky, Hannah Blencowe, Rajesh Khanna, Michael Sgro, Finn Ebbesen, Jennifer Bell, Rintaro Mori, Tina M Slusher, Nahed Fahmy, Vinod K Paul, Lizhong Du, Angela A Okolo, Maria-Fernanda de Almeida, Bolajoko O Olusanya, Praveen Kumar, Simon Cousens, Joy E Lawn
BACKGROUND: Rhesus (Rh) disease and extreme hyperbilirubinemia (EHB) result in neonatal mortality and long-term neurodevelopmental impairment, yet there are no estimates of their burden. METHODS: Systematic reviews and meta-analyses were undertaken of national prevalence, mortality, and kernicterus due to Rh disease and EHB. We applied a compartmental model to estimate neonatal survivors and impairment cases for 2010. RESULTS: Twenty-four million (18% of 134 million live births ≥ 32 wk gestational age from 184 countries; uncertainty range: 23-26 million) were at risk for neonatal hyperbilirubinemia-related adverse outcomes...
December 2013: Pediatric Research
Catherine A Hyland, Glenn J Gardener, Helen O'Brien, Glenda Millard, Kristen Gibbons, Anne Tremellen, Gorka Ochoa-Garay, Robert L Flower, Jonathan A Hyett
OBJECTIVES: Fetal RHD screening programs that aim to reduce unnecessary antenatal anti-D prophylaxis are being introduced into clinical practice. Strategies to manage women serologically typed as Rhesus D negative who have maternal RHD variants are needed. This study describes maternal RHD allelic variants detected in nonselected and alloimmunised Rhesus D negative obstetric populations and explores a mathematical approach to identify these variants. METHODS: Fetal RHD status was defined by testing cell-free fetal DNA in maternal plasma...
January 2014: Prenatal Diagnosis
Vinod K Bhutani, Ronald J Wong
Hemolytic conditions in preterm neonates, including Rhesus (Rh) disease, can lead to mortality and long-term impairments due to bilirubin neurotoxicity. Universal access to Rh immunoprophylaxis, coordinated perinatal-neonatal care, and effective phototherapy has virtually eliminated the risk of kernicterus in many countries. In the absence of jaundice due to isoimmunization and without access to phototherapy or exchange transfusion (in 1955), kernicterus was reported at 10.1%, 5.5%, and 1.2% in babies <30, 31-32, and 33-34 wks gestational age, respectively...
April 2013: Journal of Clinical Neonatology
Deepika Deka, K Aparna Sharma, Vatsla Dadhwal, Aprajita Singh, Guresh Kumar, P Vanamail
OBJECTIVES: To study the usefulness of direct fetal intravenous immunoglobulin (IVIG) infusion along with intrauterine transfusion (IUT) in the management of severe fetal anemia in rhesus (Rh) alloimmunized pregnancies. METHODS: Thirty-four consecutive Rh-isoimmunized pregnant women who required serial IUTs received either blood alone (control group, n = 16) or IVIG and blood (study group, n = 18). Pregnancies were followed up to delivery, and fetal outcome was recorded...
2013: Fetal Diagnosis and Therapy
Wenhao Xu
A 35-year-old woman with histories of frequent failed pregnancies was pregnant after having five plasma exchange procedures during which she was given Rh (D) positive plasma as replacement and her anti-D antibody titer went from 512 to 1024. Antenatal surveillance of the fetus showed no abnormality. At 36 weeks gestation she delivered an infant who initially had no significant clinical problems but was severely anemic on the following days. Using exchange transfusion and blood transfusions the infant's hemoglobin was normal at 4 months of age...
October 2013: Transfusion and Apheresis Science
Eleonor Tiblad, Magnus Westgren, Dharmintra Pasupathy, Anita Karlsson, Agneta T Wikman
OBJECTIVE: To analyze the timing of Rhesus D (RhD) immunization in pregnancy and the consequences for the index pregnancy and for subsequent pregnancies to be able to optimize the design of antenatal screening and prevention programs. DESIGN: Retrospective cohort study. SETTING: Stockholm county, Sweden. POPULATION: All RhD immunized pregnant women 1990-2008 before the introduction of routine antenatal anti-D prophylaxis...
September 2013: Acta Obstetricia et Gynecologica Scandinavica
(no author information available yet)
No abstract text is available yet for this article.
April 2013: Practising Midwife
Kerry Oxenford, Caroline Silcock, Melissa Hill, Lyn Chitty
OBJECTIVE: The goal of this study is to investigate women's preferences and information needs for routine implementation of fetal Rhesus D (RhD) typing using cell-free fetal DNA. METHODS: A questionnaire was developed following focus groups and interviews with both health professionals and RhD negative (RhD-) women offered fetal RhD genotyping within a research study and distributed to RhD- women attending routine antenatal appointments in four National Health Service hospitals...
July 2013: Prenatal Diagnosis
Laxminarayan Karanth, Sharifah Halimah Jaafar, Sachchithanantham Kanagasabai, N S Nair, Ankur Barua
BACKGROUND: During pregnancy, a Rhesus-negative (Rh-negative) woman may develop antibodies if her fetus is Rh-positive, which can cause fetal morbidity or mortality in following pregnancies, if untreated. OBJECTIVES: To assess the effects of administering anti-D immunoglobulin (Ig) after spontaneous miscarriage in a Rh-negative woman, with no anti-D antibodies. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 December 2012)...
2013: Cochrane Database of Systematic Reviews
Caroline A Crowther, Philippa Middleton, Rosemary D McBain
BACKGROUND: During pregnancy, a Rhesus negative (Rh-negative) woman may develop antibodies when her fetus is Rhesus positive (Rh-positive). These antibodies may harm Rh-positive babies. OBJECTIVES: To assess the effects of antenatal anti-D immunoglobulin on the incidence of Rhesus D alloimmunisation when given to Rh-negative women without anti-D antibodies. SEARCH METHODS: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 September 2012)...
2013: Cochrane Database of Systematic Reviews
Charles I Okwundu, Bosede B Afolabi
BACKGROUND: Antibodies to the red cell Rhesus D (RhD) antigen can be produced during pregnancy in a RhD-negative mother carrying a RhD-positive fetus, in particular following feto-maternal haemorrhage at birth or following any procedure that may cause feto-maternal haemorrhage. While the first baby is usually not harmed, these antibodies may cause haemolytic disease of the fetus/newborn (HDFN) in subsequent RhD-positive babies. RhD incompatibility is a major cause of HDFN.To reduce the risk of HDFN, anti-D is given to RhD-negative mothers at 28 or 30 weeks of pregnancy and within 72 hours of potential maternal exposure to fetal red cells...
January 31, 2013: Cochrane Database of Systematic Reviews
B Viaris de Lesegno, G Beucher, N Lamendour, M-J D'Alché-Gautier, M Dreyfus, G Benoist
OBJECTIVES: To evaluate the prevention of fetomaternal rhesus-D allo-immunization between 2008 and 2010. This evaluation was a part of the continuous medical evaluation (CME) that is compulsory in French hospitals. It was carried out using the tools recommended by the Haute Autorité de santé. We followed the national guidelines for the prevention of fetomaternal rhesus-D allo-immunization as outlined in 2005 by the national French college of Obstetrics and Gynecology. MATERIALS AND METHODS: We audited 3926 consultations in the first four months of 2008...
June 2013: Journal de Gynécologie, Obstétrique et Biologie de la Reproduction
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"